On October 15, 2014, the FDA approved Esbriet®(pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF).
IPF is a fatal disease caused by progressive scarring (fibrosis) of the lungs, which makes breathing difficult and prevents vital organs from receiving oxygen. Click here to learn more.
FDA Approves Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States
Before you take Esbriet, tell your doctor about all of your medical conditions, including if you:
You and your doctor should decide if you will take Esbriet or breastfeed.
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What should I avoid while taking Esbriet?
What are the possible side effects of Esbriet?
Esbriet may cause serious side effects, including:
The most common side effects of Esbriet include feeling tired, insomnia, upper respiratory tract infections, sinusitis, headache, dizziness, decreased weight and decreased or loss of appetite.
These are not all the possible side effects of Esbriet.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see full Prescribing Information, including Patient Information, for additional important safety information at esbriet.com.
“This is a historic day for the people and their families in the United States who live with this deadly, incurable disease. With today’s approval of Esbriet in the United States, people with IPF finally have an FDA-approved medicine that may slow the worsening of the disease.”